CXCR4 and B-cell non-Hodgkin lymphoma: In this study, we demonstrated that the CXCR4 antagonist EPI-X4 and its optimized derivative, JM#21, effectively enhance the therapeutic effects of CD19-targeted immunotherapy in B-cell lymphomas, particularly in DLBCL and WM.